FDA Issues Draft Guidance on Drug Development for Major Depressive Disorder

Drug Industry Daily
A A
The FDA published draft guidance to assist developers of monotherapeutic, combination and adjunctive drug treatments for major depressive disorder (MDD), offering considerations for nonclinical safety and clinical pharmacology.

To View This Article:

Login

Subscribe To Drug Industry Daily